Aytu Biopharma Inc (AYTU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 14,593 | 14,025 | 18,748 | 17,817 | 30,732 |
| Cost of Goods | 3,541 | 3,664 | 4,145 | 4,779 | 12,168 |
| Gross Profit | 11,052 | 10,361 | 14,603 | 13,038 | 18,564 |
| Operating Expenses | 13,866 | 12,622 | 11,602 | 14,684 | 18,563 |
| Operating Income | -2,273 | -1,597 | 3,146 | -867 | 169 |
| Interest Expense | 1,253 | 1,257 | 1,266 | 1,283 | 0 |
| Other Income | 989 | 1,087 | -481 | -5,323 | -2,626 |
| Pre-tax Income | -2,537 | -1,767 | 1,399 | -7,473 | -2,457 |
| Income Tax | 841 | 521 | 780 | 0 | N/A |
| Net Income Continuous | -3,378 | -2,288 | 619 | -7,473 | -2,457 |
| Net Income Discontinuous | -1,239 | -599 | -839 | -647 | N/A |
| Net Income | $-4,617 | $-2,887 | $-220 | $-8,120 | $-2,457 |
| EPS Basic Total Ops | -0.82 | -0.52 | -0.04 | -1.48 | -0.75 |
| EPS Basic Continuous Ops | -0.60 | -0.41 | 0.11 | -1.36 | -0.74 |
| EPS Basic Discontinuous Ops | -0.22 | -0.11 | -0.15 | -0.12 | N/A |
| EPS Diluted Total Ops | -0.82 | -0.52 | -0.04 | -1.48 | -0.75 |
| EPS Diluted Continuous Ops | -0.60 | -0.41 | 0.11 | -1.36 | -0.74 |
| EPS Diluted Discontinuous Ops | -0.22 | -0.11 | -0.15 | -0.12 | N/A |
| EPS Diluted Before Non-Recurring Items | -0.82 | -0.52 | -0.04 | N/A | N/A |
| EBITDA(a) | $-581 | $97 | $5,091 | $1,124 | $2,431 |